The Gilbert Family Foundation’s (GFF) Gene Therapy Initiative is accepting proposals for high-impact research on gene therapy strategies aimed at addressing the loss of neurofibromin 1 (NF1) gene function in neurofibromatosis type 1 (NF1) patients. This Request for Proposal (RFP) will focus on the development of therapeutic strategies, including drug delivery systems, designed to address the mutant NF1 allele or protect and/or enhance the functioning of the normal NF1 allele.
Proposals will be accepted for Team Science Awards defined as collaborative research amongst investigators with experience in gene-targeting strategies in or outside the NF1 field. There will be a two-stage peer-reviewed application process:
- In the first stage, Letters of Intent (LOIs) are due by February 28, 2021.
- GFF will select LOIs to advance and notify applicants of their application status of April 1st, 2021. For those applications selected to advance, full-length proposals will be due by May 31st, 2021.
